Tomudex (ZD1694): from concept to care, a programme in rational drug discovery

Investigational New Drugs
A L JackmanK R Harrap

Abstract

Folate-based anticancer drugs with specificity for thymidylate synthase (TS) have come of age. Ideas nurtured in the early 1970s led to the first-generation of antifolates with TS and dihydrofolate reductase (DHFR) inhibitory activities. Compounds with increased selectivity for TS followed with the highly specific inhibitor, CB3717 being synthesised in 1979 at the Institute of Cancer Research (ICR). CB3717 had significant clinical activity but its development had to be abandoned because its low aqueous solubility led to occasional nephrotoxicity. Collaborative laboratory studies between the ICR and ICI Pharmaceuticals (later to become Zeneca Pharmaceuticals) led to the discovery of ZD1694 (Tomudex), the first antifolate to be licensed for the treatment of cancer (UK 1995) in nearly 40 years and the first new drug for colorectal cancer in about 35 years. Tomudex belongs to a class of compounds that use the reduced-folate carrier (RFC) for uptake into cells and which are excellent substrates for folylpolyglutamate synthetase (FPGS). This paper reviews the underlying philosophies, and the milestones reached during the development of Tomudex.

References

Feb 1, 1978·Proceedings of the National Academy of Sciences of the United States of America·B UllmanD V Santi
Jun 1, 1977·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·R C Jackson, D Niethammer
Nov 1, 1975·The Journal of Clinical Investigation·C E MyersB A Chabner
Jan 1, 1991·Advances in Experimental Medicine and Biology·A L JackmanT C Stephens
Jan 1, 1991·Cancer Chemotherapy and Pharmacology·D I JodrellA H Calvert
May 1, 1991·Journal of Medicinal Chemistry·P R MarshamA H Calvert
Jan 1, 1989·Advances in Enzyme Regulation·K R HarrapA H Calvert
Jan 1, 1988·Cancer Chemotherapy and Pharmacology·C R FairchildJ A Straw
Jan 1, 1985·Cancer Chemotherapy and Pharmacology·D L AlisonA H Calvert
Jan 1, 1981·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·T R JonesK R Harrap
Jan 1, 1994·Cancer Treatment Reviews·G A SotosC J Allegra
Jan 1, 1993·Advances in Experimental Medicine and Biology·A L JackmanF T Boyle
Jul 1, 1995·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·A L JackmanF T Boyle
Jun 1, 1995·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·L R KellandA L Jackman
Jan 1, 1993·Advances in Experimental Medicine and Biology·S J ClarkeI R Judson
Jan 1, 1993·Advances in Experimental Medicine and Biology·S J ClarkeI R Judson
Jan 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J R Bertino
Nov 1, 1995·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·D CunninghamG Perez-Manga
Jan 1, 1996·Journal of Cancer Research and Clinical Oncology·Y TakemuraA L Jackman
Mar 28, 1996·International Journal of Cancer. Journal International Du Cancer·Y TakemuraA L Jackman
Nov 1, 1995·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A L Jackman, A H Calvert
Feb 1, 1996·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D CunninghamL Seymour

❮ Previous
Next ❯

Citations

Apr 20, 2004·Advanced Drug Delivery Reviews·Ann L JackmanDavid D Gibbs
Sep 29, 2000·Pharmacology & Therapeutics·G J PetersS P Ackland
Oct 18, 2000·Critical Reviews in Oncology/hematology·J M PadrónG J Peters
Oct 30, 2009·Expert Opinion on Drug Metabolism & Toxicology·Kenneth S Wilson, Suzanne C Malfair Taylor
May 2, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael B SawyerGini F Fleming
Jun 1, 2017·The Analyst·Nicolas GuichardSandrine Fleury-Souverain
Mar 7, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B C GohE Douglass
Feb 11, 2005·Chemical Reviews·Ivan M KompisRudolf L Then

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
D CunninghamG Perez-Manga
Annals of Oncology : Official Journal of the European Society for Medical Oncology
A L Jackman, A H Calvert
© 2021 Meta ULC. All rights reserved